Evan Ballard

Evan Ballard is a clinical researcher specialising in translational psychiatry with a research focus on rapid-acting antidepressants, principally ketamine, and their effects in major depressive disorder and bipolar disorder. His work spans clinical trials, phenomenological measurement of suicidal ideation, and mechanistic studies investigating sleep-related arousal and electrophysiological correlates of antidepressant response. Ballard has contributed to studies examining antisuicidal responses to ketamine and how these responses relate to sleep continuity, as well as methodological work on assessing suicidal ideation in trials of fast-acting treatments.

His publications and trial involvement reflect an emphasis on linking clinical outcomes (suicidality, fatigue, treatment-resistant depression) to objective measures including sleep architecture and electrophysiology, and on comparing effects in depressed versus healthy participants. Through this combination of clinical trial design, symptom measurement, and neurophysiological assessment, Ballard's contributions aid in understanding mechanisms of rapid antidepressant action and in refining biomarkers and outcome measures relevant to suicidality and sleep disturbances in mood disorders.